Lp(a) as a New Treatment Target in High-Risk CVD

The lipid particle Lp(a) emerges in several studies as a new atherogenic lipid particle that appears to be ready to be included in today’s cardiovascular risk assessment. In this talk, the current knowledge about this new lipid particle will be explored in order to understand its therapeutic ranking among the other atherogenic lipid particles. Moreover, actual and coming therapies that are effective enough to lower Lp(a) levels will be explained.

Lp(a) as a New Treatment Target in High-Risk CVD

Benoit Arsenault, PhD

Laval University

Lp(a) as a New Treatment Target in High-Risk CVD

Marcel Twickler, MD, PhD

AZ Monica, (Deurne, Antwerp) and Antwerp University